Concomitant use of β-blockers and β2-agonists

Ling Y., Saleem W., Shee C. D.

Source: Eur Respir J 2008; 31: 905-906

Journal Issue: April

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ling Y., Saleem W., Shee C. D.. Concomitant use of β-blockers and β2-agonists. Eur Respir J 2008; 31: 905-906

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Concomitant radiotherapy and targeted therapies Source: International Congress 2019 – New perspectives in thoracic surgical oncology Year: 2019
Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021
Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021
Experience of olokizumab use in COVID-19 patients Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021
Asthma and hayfever is associated with use of oral contraceptives and hormonal replacement therapy Source: Annual Congress 2003 - Risk factors for asthma Year: 2003
Daily pattern of ß2-agonists: understanding real-life use of rescue medication Source: International Congress 2017 – Asthma management Year: 2017
Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003
Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006
Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004
How can we minimise the use of regular oral corticosteroids in asthma? Source: Eur Respir Rev, 29 (155) 190085; 10.1183/16000617.0085-2019 Year: 2020
Higher effectiveness of a longer course of nicotine replacement therapy for smoking cessation Source: Eur Respir J 2006; 28: Suppl. 50, 296s Year: 2006
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Effect of Dupilumab on patient-reported breathing and rescue medication use Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
Comparison of efficacy of varenicline and nortriptyline– Short-term smoking cessation in outpatient setting Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products Year: 2016
Evaluation of the effectiveness of three different therapeutics modalities for tobacco cessation Source: Eur Respir J 2005; 26: Suppl. 49, 390s Year: 2005